Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lesinurad

FDA-approved product (tablet, oral), marketed as Zurampic.

Registered studies
22
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Lesinurad
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Gout
  • Hyperuricemia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Preparations increasing uric acid excretion
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA45.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli49.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis48.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

22registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lesinurad in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lesinurad with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Open-Label Lesinurad Monotherapy Extension Study in Gout

    NCT01650246 · start 2012-08

    Registered record
    Registry ID
    NCT01650246
    Conditions
    Gout
    Interventions
    lesinurad
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-08
    Completion
    2014-08
    Enrolment
    143

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGout
    Interventionlesinurad
    PhasePhase 3
    Registry statusCompleted

  • Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors

    NCT01508702 · start 2012-01

    Registered record
    Registry ID
    NCT01508702
    Conditions
    Gout
    Interventions
    lesinurad; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-01
    Completion
    2013-11
    Enrolment
    214

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGout
    Interventionlesinurad; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Combining Lesinurad With Allopurinol in Inadequate Responders

    NCT01510158 · start 2012-01

    Registered record
    Registry ID
    NCT01510158
    Conditions
    Gout
    Interventions
    Lesinurad; Lesinurad; Placebo; Allopurinol; Allopurinol; Allopurinol
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-01
    Completion
    2014-08
    Enrolment
    607

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGout
    InterventionLesinurad; Lesinurad; Placebo; Allopurinol +2 more
    PhasePhase 3
    Registry statusCompleted

  • Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat

    NCT01510769 · start 2012-01

    Registered record
    Registry ID
    NCT01510769
    Conditions
    Tophaceous Gout
    Interventions
    Lesinurad; Lesinurad; Placebo; Febuxostat
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-01
    Completion
    2014-06
    Enrolment
    330

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTophaceous Gout
    InterventionLesinurad; Lesinurad; Placebo; Febuxostat
    PhasePhase 3
    Registry statusCompleted

  • Combining Lesinurad With Allopurinol in Inadequate Responders

    NCT01493531 · start 2011-12

    Registered record
    Registry ID
    NCT01493531
    Conditions
    Gout
    Interventions
    Lesinurad; Lesinurad; Placebo; Allopurinol
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-12
    Completion
    2014-07
    Enrolment
    610

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGout
    InterventionLesinurad; Lesinurad; Placebo; Allopurinol
    PhasePhase 3
    Registry statusCompleted

  • Allopurinol Combination Study

    NCT01001338 · start 2009-10

    Registered record
    Registry ID
    NCT01001338
    Conditions
    Gout
    Interventions
    RDEA594; Placebo; Allopurinol
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-10
    Completion
    2016-08
    Enrolment
    227

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGout
    InterventionRDEA594; Placebo; Allopurinol
    PhasePhase 2
    Registry statusCompleted

  • Gout Dose Response Study

    NCT00955981 · start 2009-07

    Registered record
    Registry ID
    NCT00955981
    Conditions
    Hyperuricemia
    Interventions
    RDEA594; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-07
    Completion
    2011-09
    Enrolment
    123

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyperuricemia
    InterventionRDEA594; Placebo
    PhasePhase 2
    Registry statusCompleted